UCC-SMART

Data/material request form

UMC Utrecht

umcutrecht.nl

1. Request

a. Short title (max. 225 characters)

b. Contact information researcher

Name

Email address

Phone number

Organization

Division

Department

c. Supervisor

d. Involved project members

e. Funding

2. Study summary

a. Short summary (background, aim, research question, methods, outcome)

b. Rationale and goals

c. Research question

d. Lay summery in Dutch (max. 150 words)

3. Design

a. Study design

b. Study population (including in- and exclusion criteria)

c. Primary and secondary outcome measures

d. Methodological/strategic support

e. Data analysis plan

f. Potential relevance of the results of this study?

4. Specification of research data

a. Have you ever requested UCC-SMART data or material before?

☐ Yes Number of former requests

b. Of which participants would you like to receive material or data?

☐ All participants
☐ Participants with clinically manifest cardiovascular disease
A selection of patient with clinically manifest cardiovascular disease:
- ☐ Abdominal aortic aneurysm
- ☐ Cerebrovascular disease
- ☐ Coronary artery disease
- ☐ Peripheral artery disease
- ☐ Renal artery stenosis

☐ Participants with cardiovascular risk factor(s)
A selection of patient with cardiovascular risk factor(s):
- ☐ Diabetes Mellitus
- ☐ Family history
- ☐ HIV infection
- ☐ Hyperlipidemia
- ☐ Hypertension
- ☐ Hypertensive pregnancy disorder
- ☐ Renal insufficiency

c. In which subset of data are you interested?

☐ UCC-SMART data *(standard)*
☐ SMART-2 data *(repeated baseline measurement after a median of 9.9 years since inclusion in UCC-SMART, <10% of all UCC-SMART patients)*
☐ SMART-ORACLE *(additional contrast-enhanced CT of the coronary and carotid arteries on top of traditional cardiovascular risk factors in patients with a history of CVD, diabetes or hypertension)*

d. Which UCC-SMART variables would you like to receive?

☐ All health questionnaire data
A selection of health questionnaire data:
- ☐ Medical history
- ☐ Age (years)
- ☐ Sex
- ☐ Smoking and pack years
- ☐ Alcohol use and number of units
- ☐ Level of education
- ☐ Country of birth (of parents)
- ☐ Quality of life (based on EQ-5D questionnaire)
- ☐ Exercise (MET-hours per week)
- ☐ Dietary intake (only available for a subset of patients)

☐ Family cardiovascular events

☐ All anthropometric measurements

A selection of anthropometric measurements:

- ☐ Weight (kg)
- ☐ Height (m)
- ☐ Blood pressure (mmHg)
- ☐ Ankle-brachial index
- ☐ Body mass index (kg/m^2)
- ☐ Waist circumference (cm)
- ☐ Hip circumference (cm)

☐ All laboratory measurements

A selection of laboratory measurements:

- ☐ Hemoglobin (mmol/L)
- ☐ Hematocrit (%)
- ☐ Total cholesterol (mmol/L)
- ☐ LDL-C (mmol/L)
- ☐ HDL-C (mmol/L)
- ☐ Apolipoprotein B (g/L)
- ☐ Triglycerides (mmol/L)
- ☐ HbA1c (%)
- ☐ Fasting glucose (mmol/L)
- ☐ Fasting insulin (mU/L)
- ☐ Creatinine (µmol/L)
- ☐ eGFR (ml/min/1.73 m2)
- ☐ Albuminuria (mg/L)
- ☐ Albumin-to-creatinine ratio
- ☐ CRP (mg/L)
- ☐ TSH (mU/L)

☐ All radiology measurements

A selection of radiology measurements:

- ☐ Visceral fat (cm)
- ☐ Subcutaneous fat (cm)
- ☐ Carotid artery stenosis (%)
- ☐ Carotid intima thickness (mm)
- ☐ Aortic artery diameter (cm)
- ☐ Kidney size and volume (cm; mL)
- ☐ Electrocardiography
- ☐ Echocardiography (only available for a subset of patients)

☐ All medication use

A selection of medication use:

- ☐ Statins
- ☐ Ezetimibe
- ☐ Fibrates
- ☐ Thiazide diuretics
- ☐ Loop diuretics
- ☐ Potassium saving diuretics
- ☐ ACE-inhibitors
- ☐ Angiotensin II-receptor blockers

- ☐ Aldosterone antagonists
- ☐ Beta-blockers
- ☐ Calcium antagonists
- ☐ Alpha blockers
- ☐ Central acting antihypertensives
- ☐ Direct vasodilators
- ☐ Aspirin
- ☐ Clopidogrel
- ☐ Dipyridamole
- ☐ DOAC
- ☐ Vitamin K antagonists
- ☐ LMWH

☐ All follow-up/outcome events

A selection of follow-up/outcome events:

- ☐ Stroke
  - ☐ Ischemic stroke/hemorrhagic infarction
  - ☐ Cerebral hemorrhage
  - ☐ Subarachnoid hemorrhage
  - ☐ Type not determined
- ☐ Retinal syndromes
  - ☐ Infarction
  - ☐ Hemorrhage
- ☐ Myocardial infarction
  - ☐ STEMI
  - ☐ NSTEMI
  - ☐ Intervention-related myocardial infarction
  - ☐ Probable myocardial infarction
- ☐ Heart failure
- ☐ Rupture of abdominal aortic aneurysm
- ☐ Renal disease
  - ☐ End-stage renal disease
  - ☐ Acute renal insufficiency – temporary renal replacement therapy
  - ☐ Acute renal insufficiency – no renal replacement therapy
- ☐ Bleeding
  - ☐ Major bleeding
- ☐ Diabetes
  - ☐ DM type 1
  - ☐ DM type 2
- ☐ Vascular mortality
  - ☐ Fatal cerebral infarction
  - ☐ Fatal cerebral hemorrhage
  - ☐ Fatal stroke - type not determined
  - ☐ Fatal myocardial infarction
  - ☐ Fatal heart failure
  - ☐ Fatal rupture abdominal aortic aneurysm
  - ☐ Fatal bleeding
  - ☐ Sudden death
  - ☐ Other
- ☐ Non-vascular mortality
- ☐ All-cause mortality
- ☐ Amputation

☐ Vascular intervention
☐ Vascular intervention of an intracranial aneurysm

Other/advanced measurements/diagnostic tests (please specify)

e. Collaboration (if yes, please specify)

5. Specification of requested material

a. Kind and amount of material requested

Citrate plasma	EDTA plasma	EDTA cell-pellet	Serum
Amount (µl)	Amount (µl)	Amount (µl)	Amount (µl)
Number of patients	Number of patients	Number of patients	Number of patients

b. Is there approval of the TCBio yet?

☐ Yes ☐ No

6. Time frame

a. When is the data needed?

7. Code of Conduct

In order to work with data or material of the Utrecht Cardiovascular Cohorts - SMART (UCC-SMART) of the UMC Utrecht you need to comply with the terms and conditions as stated in the UCC-SMART Code of Conduct.

8. Cohort Profile

For more information on the rationale, design, included patients, measurments and findings of the cohort from 1996 untill 2023 we refer you to the recent Cohort Profile.